Feasibility of a Single-operator Peroral Cholangiopancreatioscopy System (SpyGlass)
Status: | Recruiting |
---|---|
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 8/23/2018 |
Start Date: | July 2015 |
End Date: | July 2020 |
Contact: | Srinadh Komanduri, MD |
Email: | koman1973@gmail.com |
Phone: | 312-695-0484 |
Clinical Feasibility and Efficacy of a New Digital Single-operator Peroral Cholangiopancreatioscopy System: a Multicenter Registry
Cholangioscopy, or direct visualization of the bile ducts was first documented in the late
1970s and has made many advances over the last few decades. The advent of mother-baby scopes
allowed for both diagnostic and therapeutic procedures, though the early scopes were often
fragile, and cumbersome due to the need for two endoscopists. Ultraslim endoscopes later
became popular as a method to digitally view the bile ducts, however, often needed guide-wire
or balloon-assistance to allow for cannulation. Other disadvantages of these systems included
limited steerability, and poor irrigation capabilities.
The advent of Spyglass, a single-operator peroral cholangioscopy method allowed for a
fiberoptic, catheter-based system that could be easily used for diagnostic and therapeutic
purposes in the biliary system. However, image quality was often lacking due to the
fiberoptic technology. The new digital Spyglass system rectifies this inadequacy by
introducing a digital sensor for better image quality, which will allow for better
visualization and diagnosis of indeterminate strictures. Furthermore, modification of the
scope platform allows for efficient use, reliable directionality of the scope tip, and
improved ease of passage of accessories during therapeutic procedures such clearing stones or
stent placement.
1970s and has made many advances over the last few decades. The advent of mother-baby scopes
allowed for both diagnostic and therapeutic procedures, though the early scopes were often
fragile, and cumbersome due to the need for two endoscopists. Ultraslim endoscopes later
became popular as a method to digitally view the bile ducts, however, often needed guide-wire
or balloon-assistance to allow for cannulation. Other disadvantages of these systems included
limited steerability, and poor irrigation capabilities.
The advent of Spyglass, a single-operator peroral cholangioscopy method allowed for a
fiberoptic, catheter-based system that could be easily used for diagnostic and therapeutic
purposes in the biliary system. However, image quality was often lacking due to the
fiberoptic technology. The new digital Spyglass system rectifies this inadequacy by
introducing a digital sensor for better image quality, which will allow for better
visualization and diagnosis of indeterminate strictures. Furthermore, modification of the
scope platform allows for efficient use, reliable directionality of the scope tip, and
improved ease of passage of accessories during therapeutic procedures such clearing stones or
stent placement.
All patients referred for the evaluation of indeterminate strictures or removal of difficult
stones will be eligible for enrollment in the consortium. The PI or study coordinator will
meet with the patient and discuss the study, its objectives, and obligations with each
patient. After full disclosure, informed consent will be obtained.
Upon consent, basic demographics and data from prior procedures (when available) will be
recorded. An endoscopist proficient in ERCP, with expertise in cholangioscopy, will perform
the procedures using the Spyglass DS system with its associated components including biopsy
forceps (SpyBiteTM) and other accessories as necessary. Procedure time, visual findings,
number of biopsies taken, pathology, stone location, stone size, and method of stone
clearance and adverse events will be recorded on data collection forms and transferred into a
centralized password protected database. All patients will be followed for 6-12 months or
surgery (stricture cohort) to assess accuracy or stone recurrence rates.
stones will be eligible for enrollment in the consortium. The PI or study coordinator will
meet with the patient and discuss the study, its objectives, and obligations with each
patient. After full disclosure, informed consent will be obtained.
Upon consent, basic demographics and data from prior procedures (when available) will be
recorded. An endoscopist proficient in ERCP, with expertise in cholangioscopy, will perform
the procedures using the Spyglass DS system with its associated components including biopsy
forceps (SpyBiteTM) and other accessories as necessary. Procedure time, visual findings,
number of biopsies taken, pathology, stone location, stone size, and method of stone
clearance and adverse events will be recorded on data collection forms and transferred into a
centralized password protected database. All patients will be followed for 6-12 months or
surgery (stricture cohort) to assess accuracy or stone recurrence rates.
Inclusion Criteria:
- All patients referred for the evaluation of indeterminate strictures or removal of
difficult stones.
Exclusion Criteria:
- All patients who are unable or unwilling to give consent will not be included in this
study
We found this trial at
5
sites
Denver, Colorado 80291
Principal Investigator: Sachin Wani, MD
Phone: 720-848-2786
Click here to add this to my saved trials
201 Presidents Circle
Salt Lake City, Utah 84108
Salt Lake City, Utah 84108
801) 581-7200
Principal Investigator: Douglas Adler, MD
Phone: 801-213-9797
University of Utah Research is a major component in the life of the U benefiting...
Click here to add this to my saved trials
757 Westwood Plaza
Los Angeles, California 90024
Los Angeles, California 90024
(310) 825-9111
Principal Investigator: V. Raman Muthusamy, MD
Phone: 310-825-1892
UCLA Medical Center Founded in 1955, UCLA Medical Center became Ronald Reagan UCLA Medical Center...
Click here to add this to my saved trials
1514 Jefferson Hwy.
New Orleans, Louisiana 70121
New Orleans, Louisiana 70121
504-842-3000
Principal Investigator: Janak N. Shah, MD
Ochsner Medical Center Ochsner Medical Center is located near uptown New Orleans and includes acute...
Click here to add this to my saved trials
Tampa, Florida 33612
Principal Investigator: Jason Klapman, MD
Phone: 813-745-8361
Click here to add this to my saved trials